Alain Luxembourg

5.3k total citations
76 papers, 1.8k citations indexed

About

Alain Luxembourg is a scholar working on Epidemiology, Immunology and Surgery. According to data from OpenAlex, Alain Luxembourg has authored 76 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Epidemiology, 24 papers in Immunology and 11 papers in Surgery. Recurrent topics in Alain Luxembourg's work include Cervical Cancer and HPV Research (49 papers), Hepatitis B Virus Studies (44 papers) and Immunotherapy and Immune Responses (19 papers). Alain Luxembourg is often cited by papers focused on Cervical Cancer and HPV Research (49 papers), Hepatitis B Virus Studies (44 papers) and Immunotherapy and Immune Responses (19 papers). Alain Luxembourg collaborates with scholars based in United States, Colombia and Denmark. Alain Luxembourg's co-authors include Drew Hannaman, Neil R. Cooper, Barry Ellefsen, Erin Moeller, Claire F. Evans, Pierre Van Damme, Oliver Bautista, Anna R. Giuliano, Roger Maansson and Alfred J. Saah and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Nature Biotechnology.

In The Last Decade

Alain Luxembourg

74 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alain Luxembourg United States 27 1.2k 523 366 239 208 76 1.8k
Frances B. Alvarez United States 8 1.8k 1.6× 482 0.9× 648 1.8× 76 0.3× 176 0.8× 8 2.1k
Frank Struyf Belgium 23 1.4k 1.2× 365 0.7× 498 1.4× 129 0.5× 185 0.9× 60 1.7k
Martine Wettendorff Belgium 16 785 0.7× 666 1.3× 116 0.3× 196 0.8× 287 1.4× 24 1.4k
Judith F. Smith United States 16 1.0k 0.9× 366 0.7× 330 0.9× 72 0.3× 193 0.9× 18 1.4k
D R Lowy United States 9 1.2k 1.0× 551 1.1× 265 0.7× 79 0.3× 248 1.2× 12 1.5k
Merilyn Hibma New Zealand 22 810 0.7× 412 0.8× 174 0.5× 63 0.3× 376 1.8× 56 1.4k
Diane M. Da Silva United States 28 1.0k 0.9× 1.2k 2.3× 168 0.5× 111 0.5× 531 2.6× 63 2.1k
Peggy Riese Germany 18 401 0.3× 1.2k 2.3× 79 0.2× 181 0.8× 209 1.0× 41 1.6k
Maria Gabriella Donà Italy 20 667 0.6× 85 0.2× 402 1.1× 87 0.4× 188 0.9× 72 1.1k
M E Hagensee United States 16 750 0.7× 217 0.4× 204 0.6× 146 0.6× 239 1.1× 18 1.2k

Countries citing papers authored by Alain Luxembourg

Since Specialization
Citations

This map shows the geographic impact of Alain Luxembourg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alain Luxembourg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alain Luxembourg more than expected).

Fields of papers citing papers by Alain Luxembourg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alain Luxembourg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alain Luxembourg. The network helps show where Alain Luxembourg may publish in the future.

Co-authorship network of co-authors of Alain Luxembourg

This figure shows the co-authorship network connecting the top 25 collaborators of Alain Luxembourg. A scholar is included among the top collaborators of Alain Luxembourg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alain Luxembourg. Alain Luxembourg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Smith, Robin A.J., Erin M. Scherer, David Skibinski, et al.. (2025). Term immune memory responses to human papillomavirus (HPV) vaccination following 2 versus 3 doses of HPV vaccine. Vaccine. 50. 126817–126817. 1 indexed citations
2.
Joura, Elmar A., Susanne K. Kjær, Oliver Bautista, et al.. (2025). Effect of Prior 9-Valent Human Papillomavirus Vaccination on Subsequent Lower Genital Tract Dysplasia After Cervical Excisional Surgery. Obstetrics and Gynecology. 147(1). 73–82.
3.
Kjær, Susanne K., Karin Sundström, Christian Munk, et al.. (2024). Long-term effectiveness of the nine-valent human papillomavirus vaccine: Interim results after 12 years of follow-up in Scandinavian women. Human Vaccines & Immunotherapeutics. 20(1). 2377903–2377903. 7 indexed citations
4.
Wang, Wei, Smita Kothari, Jozica Skufca, et al.. (2022). Real-world impact and effectiveness of the quadrivalent HPV vaccine: an updated systematic literature review. Expert Review of Vaccines. 21(12). 1799–1817. 33 indexed citations
5.
Lv, Huakun, Shenyu Wang, Zhenzhen Liang, et al.. (2022). Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9–45 years of age: A phase 3 open-label study. Vaccine. 40(23). 3263–3271. 10 indexed citations
6.
Giuliano, Anna R., Elmar A. Joura, Alex Ferenczy, et al.. (2022). Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years. Human Vaccines & Immunotherapeutics. 18(5). 2078626–2078626. 20 indexed citations
7.
Thiểm, Vũ Đình, et al.. (2021). Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial. Human Vaccines & Immunotherapeutics. 17(7). 1980–1985. 2 indexed citations
8.
Giuliano, Anna R., Timothy Wilkin, Oliver Bautista, et al.. (2021). Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men. Contemporary Clinical Trials. 115. 106592–106592. 23 indexed citations
9.
Kjær, Susanne K., Mari Nygård, Karin Sundström, et al.. (2020). Long-term effectiveness of the nine-valent human papillomavirus vaccine in Scandinavian women: interim analysis after 8 years of follow-up. Human Vaccines & Immunotherapeutics. 17(4). 943–949. 34 indexed citations
10.
Giuliano, Anna R., Elmar A. Joura, Suzanne M. Garland, et al.. (2019). Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. Gynecologic Oncology. 154(1). 110–117. 63 indexed citations
11.
Saah, Alfred J., Oliver Bautista, Alain Luxembourg, & Gonzalo Pérez. (2017). Intention-to-prevent analyses for estimating human papillomavirus vaccine efficacy in clinical studies. Contemporary Clinical Trials Communications. 7. 189–193. 2 indexed citations
12.
Damme, Pierre Van, Chris J.L.M. Meijer, Dorothee Kieninger, et al.. (2016). A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine. 34(35). 4205–4212. 57 indexed citations
13.
Vesikari, Timo, Nicholas Brodszki, Pierre Van Damme, et al.. (2015). A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9–15-Year-Old Girls. The Pediatric Infectious Disease Journal. 34(9). 992–998. 79 indexed citations
14.
Pitisuttithum, Punnee, Christine Velicer, & Alain Luxembourg. (2015). 9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV. Expert Review of Vaccines. 14(11). 1405–1419. 35 indexed citations
15.
Buronfosse, Thierry, Catherine Jamard, Sylviane Guérret, et al.. (2012). Enhanced magnitude and breadth of neutralizing humoral response to a DNA vaccine targeting the DHBV envelope protein delivered by in vivo electroporation. Virology. 425(1). 61–69. 11 indexed citations
16.
17.
Luxembourg, Alain, Drew Hannaman, Ken N. Wills, et al.. (2008). Immunogenicity in mice and rabbits of DNA vaccines expressing woodchuck hepatitis virus antigens. Vaccine. 26(32). 4025–4033. 18 indexed citations
18.
Cai, Zeling, Anders Brunmark, Alain Luxembourg, et al.. (1998). Probing the activation requirements for naive CD8+ T cells with Drosophila cell transfectants as antigen presenting cells. Immunological Reviews. 165(1). 249–265. 26 indexed citations
19.
Roberts, M. L., Alain Luxembourg, & Neil R. Cooper. (1996). Epstein--Barr virus binding to CD21, the virus receptor, activates resting B cells via an intracellular pathway that is linked to B cell infection. Journal of General Virology. 77(12). 3077–3085. 21 indexed citations
20.
Luxembourg, Alain. (1988). Intracellular metabolism of the interferon mediator, 2-5A, using permeabilized cells. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 951(1). 175–181. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frances B. Alvarez Breakdown of academic impact, for papers by Frank Struyf Breakdown of academic impact, for papers by Martine Wettendorff Breakdown of academic impact, for papers by Judith F. Smith Breakdown of academic impact, for papers by D R Lowy Breakdown of academic impact, for papers by Merilyn Hibma Breakdown of academic impact, for papers by Diane M. Da Silva Breakdown of academic impact, for papers by Peggy Riese Breakdown of academic impact, for papers by Maria Gabriella Donà Breakdown of academic impact, for papers by M E Hagensee
Rankless by CCL
2026